Related Experiment Video
Updated: May 23, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent
Masahide Odan1, Natsuki Ishizuka, Yoshiharu Hiramatsu
1Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd 1-1, Toyonaka, Osaka, Japan. masahide.oodan@shionogi.co.jp
Abstract:
The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivatives by adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure-activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compound 48/80 at 1.0 mg/kg po and 10 mg/kg po (55% and 61%, respectively).
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cholinergic Antagonists: Pharmacokinetics
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists